ReviewTissue engineering and regenerative medicine2023
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.
Review in Tissue engineering and regenerative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions.Biomarker research · 2026Review
- Nanotechnology-enabled immunomodulation in esophageal cancer: targeting the tumor microenvironment to overcome therapeutic barriers.Frontiers in immunology · 2026Review
- The Nanoparticle Delivery Gap in Immune Cell Engineering: From Uptake to Endosomal Escape.International journal of nanomedicine · 2026Review
- Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.Frontiers in immunology · 2026Review
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- In vivo CAR engineering for immunotherapy.Nature reviews. Immunology · 2025Review
- Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer.Clinical and experimental medicine · 2025Review
- From lab to lifesaver: the rise of CAR T-cell therapy in oncology.Journal of the Egyptian National Cancer Institute · 2025Review
- Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025Review
- Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.Nano convergence · 2024Review
- A translational framework to DELIVER nanomedicines to the clinic.Nature nanotechnology · 2024Review
- The next frontier in immunotherapy: potential and challenges of CAR-macrophages.Experimental hematology & oncology · 2024Review
- Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.EBioMedicine · 2024Review
- M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Article
- Steering the course of CAR T cell therapy with lipid nanoparticles.Journal of nanobiotechnology · 2024Review
- Shifting the paradigm: engaging multicellular networks for cancer therapy.Journal of translational medicine · 2024Review
- Immunotherapy Study on Non-small-Cell Lung Cancer (NSCLC) Combined with Cytotoxic T Cells and miRNA34a.Molecular pharmaceutics · 2024Article
- Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.